DOUBLE BLIND, RANDOMIZED, MULTICENTER, PLACEBO CONTROLLED PARALLEL AND ACTIVE CONTROLLER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-0767 IN THE ALTERATION OF GLUCOSE AND LIPIDS IN PATIENTS THAT HAVE TYPE 2 DIABETES.
Phase 1
Completed
- Conditions
- -E149 Unspecified diabetes mellitus, without complicationsUnspecified diabetes mellitus, without complicationsE149
- Registration Number
- PER-006-03
- Lead Sponsor
- MERCK SHARP & DOHME PERU S.R.L.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. End the initial double-blind study.
2. Have met> 75% of study medication during the double-blind period of the baseline study.
3. Understanding of study procedures and agreement to participate in the study granting written informed consent.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MK-0767 target to alter glucose and lipid metabolism in type 2 diabetes?
How does MK-0767 compare to GLP-1 receptor agonists in glycemic control and lipid profile improvement for T2DM patients?
Which biomarkers are associated with response to MK-0767 in type 2 diabetes clinical trials?
What adverse events were observed in phase I trials of MK-0767 for metabolic disorders?
Are there combination therapies involving MK-0767 and SGLT2 inhibitors that enhance glucose-lipid regulation in T2DM?